Bacteria in the genus Yersinia cause a range of human diseases, including bubonic and pneumonic plague, infections of the intestinal lymphoid system, and lethal systemic infections. A number of virulence factors are common to pathogenic Yersinia species, including a type 3 secretion system (TTSS), and a set of secreted proteins known as the Yops and LcrV. Yersinia use the TTSS to deliver several Yop effector proteins (e.g. Yops E, H and J) into host cells. Delivery of the Yop effectors requires several additional proteins including Yops B and D, and LcrV. The effector Yops act within host cells to thwart innate immune responses through interference with signal transduction pathways. The TTSS is required for sustained replication of Yersinia in host lymphoid tissues. Two cytokines, tumor necrosis factor alpha (TNF) and interferon gamma (IFN), are essential for development of protective immune responses to Yersinia. However, Yersinia use the TTSS to counteract production of TNF and IFN in lymphoid tissues. The results of in vivo studies suggest that either LcrV or YopB are directly responsible for counteracting cytokine production. The results of in vitro experiments using cultured cells as infection models show that Yops E, H and J are directly responsible for counteracting cytokine production, and YopB and LcrV function only to mediate delivery of the effectors. Thus, there is a significant disagreement in the field concerning the mechanism used by Yersinia to counteract cytokine production by host cells. We .will utilize isogenic wild-type, Yop mutant and LcrV mutant Yersinia strains and a mouse intestinal infection model to determine how the Yops and LcrV function to counteract cytokine production in vivo.
In aim 1, host cell types that interact with wild-type or Yop mutant Yersinia in tissues of mice will be identified. These studies will identify host cell types that are targets of Yops in vivo.
In aim 2, levels of TNF and IFN in tissues of mice infected with wild-type, Yop mutant or LcrV mutant Yersinia will be measured. Our results will elucidate an essential mechanism of Yersinia pathogenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI043389-06
Application #
6875517
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Program Officer
Alexander, William A
Project Start
2000-02-01
Project End
2010-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
6
Fiscal Year
2005
Total Cost
$343,969
Indirect Cost
Name
State University New York Stony Brook
Department
Genetics
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Zheng, Ying; Lilo, Sarit; Brodsky, Igor E et al. (2011) A Yersinia effector with enhanced inhibitory activity on the NF-?B pathway activates the NLRP3/ASC/caspase-1 inflammasome in macrophages. PLoS Pathog 7:e1002026
Zhang, Yue; Bliska, James B (2011) Mathematical relationship between cytokine concentrations and pathogen levels during infection. Cytokine 53:158-62
Zhang, Yue; Romanov, Galina; Bliska, James B (2011) Type III secretion system-dependent translocation of ectopically expressed Yop effectors into macrophages by intracellular Yersinia pseudotuberculosis. Infect Immun 79:4322-31
Zhang, Yue; Bliska, James B (2010) YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection. Infect Immun 78:2329-41
Brodsky, Igor E; Palm, Noah W; Sadanand, Saheli et al. (2010) A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. Cell Host Microbe 7:376-87
McPhee, Joseph B; Mena, Patricio; Bliska, James B (2010) Delineation of regions of the Yersinia YopM protein required for interaction with the RSK1 and PRK2 host kinases and their requirement for interleukin-10 production and virulence. Infect Immun 78:3529-39
Okan, Nihal A; Mena, Patricio; Benach, Jorge L et al. (2010) The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection. Infect Immun 78:1284-93
Noel, Betty L; Lilo, Sarit; Capurso, Daniel et al. (2009) Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages. Clin Vaccine Immunol 16:1457-66
Zhang, Yue; Murtha, James; Roberts, Margaret A et al. (2008) Type III secretion decreases bacterial and host survival following phagocytosis of Yersinia pseudotuberculosis by macrophages. Infect Immun 76:4299-310
Lilo, Sarit; Zheng, Ying; Bliska, James B (2008) Caspase-1 activation in macrophages infected with Yersinia pestis KIM requires the type III secretion system effector YopJ. Infect Immun 76:3911-23

Showing the most recent 10 out of 24 publications